HCPCS Code J0139: Injection, adalimumab, 1 mg billing guide (Formerly J0135)

Key takeaways

HCPCS Code J0139 (“Injection, adalimumab, 1 mg”) is the current code for adalimumab; it replaced the deleted J0135 effective January 1, 2025.

The unit basis changed from 20 mg per unit to 1 mg per unit. A standard 40 mg Humira dose is now billed as 40 units, not 2 units.

J0135’s last valid date of service was December 31, 2024. CMS allows no grace period, so a 2025 or later claim billed as J0135 is rejected as an invalid code.

Practice management software like Pabau supports adalimumab billing with treatment notes, digital forms, and record-keeping that document each administration.

Under Medicare Part B and most commercial payers, adalimumab is billed using the buy-and-bill model. The practice purchases the drug, administers it, and seeks reimbursement through its billing system or clearinghouse.

This guide covers the unit calculation, the biosimilar Q-code crosswalk, Medicare reimbursement, and prior authorization requirements billers need for a clean J0139 claim.

HCPCS Code J0139: Definition and clinical overview

HCPCS Code J0139 is the current Level II J-code for injection of adalimumab, 1 mg, effective January 1, 2025. It replaced J0135 (“Injection, adalimumab, 20 mg”), which CMS deleted with a last valid date of service of December 31, 2024. Adalimumab is a tumor necrosis factor (TNF)-alpha inhibitor biologic administered by subcutaneous injection in physician office and outpatient settings.

The Centers for Medicare and Medicaid Services (CMS) maintains the HCPCS Level II code set. J-codes specifically cover drugs administered by a healthcare professional in a clinical setting, which is why pharmacy-dispensed, self-injected adalimumab follows a different coverage pathway.

Clinical indications: When is it used?

Adalimumab is FDA-approved for multiple autoimmune conditions. Billers should pair each J0139 claim with a diagnosis code that matches an FDA-approved indication and falls within the payer’s covered diagnoses list. Submitting J0139 against an unsupported diagnosis code is a leading cause of medical necessity denials.

• Rheumatoid arthritis (RA)
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn’s disease
• Ulcerative colitis
• Plaque psoriasis
• Juvenile idiopathic arthritis
• Hidradenitis suppurativa
• Non-infectious uveitis

ICD-10 codes billed with adalimumab

The table below maps the most commonly billed ICD-10-CM diagnosis codes to their J0139 indications. Always verify against the specific payer’s local coverage determination (LCD) before submitting.

Billing guidelines for adalimumab injections

Biologic J-code billing has more moving parts than a standard E/M or procedure claim. Four variables drive most J0139 denials: wrong unit count, missing NDC number, incorrect place of service, and absent prior authorization documentation. Careful clinical documentation catches these errors before the claim leaves the practice.

How to calculate the billing units

J0139 is billed per 1 mg of adalimumab administered, not per 20 mg like the deleted J0135. This is the single most consequential change for billers. The standard adult 40 mg Humira dose, once billed as 2 units under J0135, is billed as 40 units under J0139. A biller who reports 2 units out of old habit effectively bills 2 mg instead of 40 mg. That biller gets paid roughly 5% of the drug’s value.

NDC crosswalk for adalimumab products

Medicare and many commercial payers require the National Drug Code (NDC) on the claim line alongside J0139. The NDC identifies the exact adalimumab product administered, which matters when a biosimilar is dispensed rather than reference Humira. Record the NDC from the vial or pre-filled syringe used at the time of administration, so it is available when the claim is prepared.

NDC numbers change with new lot releases and formulation updates. Always verify current NDCs directly via the FDA’s Orange Book or the manufacturer’s current package insert rather than relying on a static crosswalk table. Outdated NDC submissions are a documented cause of claim rejections.

Medicare reimbursement rules

Medicare Part B reimburses physician-administered biologics like J0139 using the Average Sales Price (ASP) methodology. The statutory formula is ASP plus 6%. Because ASP is recalculated quarterly by CMS, the payment rate for J0139 changes four times per year. Never rely on a hardcoded dollar figure in a billing reference. Always consult the current CMS ASP pricing files for the active quarter’s payment amount.

Reimbursement also varies by place of service. Non-facility rates (physician office, POS 11) generally differ from facility rates (hospital outpatient, POS 22). Practices billing from an office setting should confirm which rate applies to their POS code before projecting reimbursement against drug acquisition cost. The 1 mg unit basis makes this comparison more granular than it was under J0135.

Prior authorization requirements for adalimumab

Prior authorization (PA) is typically required for adalimumab under most commercial payer plans and many Medicare Advantage plans. Standard PA documentation requirements commonly include diagnosis confirmation, evidence of failed prior conventional therapy (step therapy), and the prescribing clinician’s attestation of medical necessity. Thorough clinical documentation of treatment history strengthens PA requests.

• Step therapy: Most payers require documented failure of at least one conventional DMARD (e.g. methotrexate) before approving adalimumab for RA.
• PA validity period: Authorizations are typically granted for 6-12 months. Renewal documentation is required at each cycle.
• Medicare FFS: Traditional Medicare does not require PA for Part B drugs, but Medicare Advantage plans may impose their own requirements.
• Commercial payers: Requirements vary significantly. Always verify with the specific plan before administering the drug.

Adalimumab biosimilar codes

Multiple adalimumab biosimilars, FDA-approved between 2016 and 2019, began launching commercially in 2023 after patent settlements with AbbVie. On January 1, 2025, CMS moved the entire adalimumab biosimilar family onto product-specific Q-codes billed on a 1 mg unit basis. This replaced the earlier codes that used a 20 mg or 10 mg basis. Billers using an old code or the wrong unit basis for a biosimilar will see claim edits from payers. Those payers now expect the current Q-code and unit count.

Not all adalimumab biosimilars hold FDA-designated interchangeable status, and state pharmacy substitution laws vary. Billers should confirm both the biosimilar’s FDA approval status and the applicable payer code policy before selecting a code. Several of these Q-codes were deleted and renumbered onto a 1 mg basis on the same date J0135 was deleted.

Is J0135 deleted? What billers should know

Yes. CMS deleted J0135 with a last valid date of service of December 31, 2024. J0139 (“Injection, adalimumab, 1 mg”) replaced it, effective January 1, 2025. AAPC’s code database lists J0135 under its deleted-code path, and MAC bulletins including CGS’s and NGS’s January 2025 HCPCS updates confirm the change. CMS allows no grace period for a deleted J-code. Any adalimumab claim with a 2025 or later date of service billed as J0135 is rejected as an invalid code.

• Bill any date of service on or after January 1, 2025 as J0139, at 1 mg per unit.
• Bill any date of service on or before December 31, 2024 as J0135, at 20 mg per unit, for historical claims and appeals.
• If a remittance still references J0135 for a 2025 or later date of service, that reflects payer lag in updating their own systems. Follow up with the payer directly.
• Update superbills, chargemasters, and EHR order sets that still reference J0135 so staff default to J0139 going forward.

Self-administered drug exclusion rules

Medicare Part B covers drugs that cannot be self-administered by the typical patient. Adalimumab is a subcutaneous injection that many patients self-administer at home. CMS Article A53066 (Self-Administered Drug Exclusion List) governs when Part B coverage applies. The critical distinction is setting. Office-administered adalimumab, injected by a clinician or trained staff in a physician office, is eligible for Part B coverage and J0139 billing. Home self-injection, by contrast, is typically excluded from Part B and covered under Medicare Part D instead. Practices that both administer in-office and dispense for home use must document clearly which administration route applies to each claim.

How practice management software supports adalimumab billing

Biologic billing errors are disproportionately expensive. A single denied adalimumab claim represents hundreds or thousands of dollars in drug cost that the practice has already absorbed. The documentation burden for J0139 is higher than a standard office visit. Unit calculation, NDC capture, prior authorization status, ICD-10 pairing, and place of service all need to be correct simultaneously.

Practice management software like Pabau supports this documentation burden across the specialties that administer adalimumab most. That includes dermatology practices treating plaque psoriasis and general practices managing broader biologic caseloads.

When adalimumab is administered, staff can record the treatment note, dose, and product details directly against the client’s record. The clinical detail a biller needs is already attached to the encounter.

Digital consent and intake forms capture the diagnosis and treatment history that supports medical necessity. Every note stays tied to the client’s file for audit readiness. The billing system still handles unit calculation and clearinghouse submission. This just connects what happened in the treatment room to what the billing team needs to find afterward.

Keep adalimumab documentation attached to every claim

Pabau's treatment notes, digital forms, and client records keep the dose, lot, and consent details from each adalimumab administration attached to the client's file, so your billing team has the documentation a J0139 claim needs without digging through separate systems.

Book a demo

Conclusion

Adalimumab billing is unforgiving. Wrong units, an expired code, or a lapsed prior authorization each produce an avoidable denial on a high-cost drug the practice has already purchased. The move from J0135 to J0139 is the biggest change adalimumab billers face this cycle. The unit basis dropped from 20 mg to 1 mg per unit. CMS allows no grace period for claims still billed under the deleted code.

Practice management software like Pabau keeps the treatment note, dose, and consent documentation attached to each client’s file. The clinical detail behind a J0139 claim is then easy for billing staff to find and verify. To see how Pabau supports clinical documentation for biologic treatments, book a demo.

Continue your research

Treating a papulosquamous skin condition alongside adalimumab? ICD-10 Code L45 covers the diagnosis codes billers pair with psoriasis-driven biologic claims.

Also billing for an implantable neurostimulator? HCPCS Code C1826 walks through billing an implantable neurostimulator generator.

Coding a debridement procedure in the same visit? CPT Code 11011 covers debridement of an open fracture, including current fee schedule modifiers.

Documenting a patient’s baseline mobility before a biologic? Range of motion assessment is a clinical guide practitioners use to track functional status.

Coding another autoimmune connective tissue diagnosis? ICD-10 Code M35.5 covers multifocal fibrosclerosis, a related autoimmune billing scenario.

Frequently asked questions